Geron Corporation
149 Commonwealth Drive
Suite 2070
Menlo Park,
CA 94025
United States - Map
Phone: 650-473-7700
Fax: 650-473-7750
Website: http://www.geron.com
Geron Corporation, a biopharmaceutical company, develops therapies for cancer. Its clinical development product candidate includes Imetelstat, a telomerase inhibitor, which is in Phase II clinical trials for the treatment of advanced non-small cell lung cancer, essential thrombocythemia, and multiple myeloma. The company was founded in 1990 and is based in Menlo Park, California. Key Statistics
| |
| Geron Corporation’s ISS Governance QuickScore as of Jun 1, 2013 is 8. The pillar scores are Audit: 1; Board: 3; Shareholder Rights: 7; Compensation: 9. | | Brought to you by Institutional Shareholder Services (ISS) |
| | Pay | Exercised | Dr. John A. Scarlett M.D.,
62
Chief Exec. Officer, Pres and Director | 934.00K | 0.00 | Ms. Olivia Kyusuk Bloom ,
44
Chief Financial Officer, Principal Accounting Officer, Sr. VP of Fin. and Treasurer | 404.00K | 0.00 | Mr. Stephen N. Rosenfield J.D.,
63
Exec. VP, Gen. Counsel and Corp. Sec. | 501.00K | 0.00 | Dr. Andrew J. Grethlein Ph.D.,
49
Acting Head of Research and Exec. VP of Technical Operations | 152.00K | 0.00 | Anna Krassowska Ph.D.,
Investor and Media Relations Officer | N/A | N/A |
|
| | Amounts are as of Dec 30, 2012 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year. | | Currency in USD. |
|
0.91%